Clinical trial
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent…
NCT00039052 · Neurocrine Biosciences, Industry · Completed
Key facts
| NCT number | NCT00039052 |
|---|---|
| Title | Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer |
| Official title | An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors |
| Lead sponsor | Neurocrine Biosciences, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Kidney Cancer, Lung Cancer |
| Intervention type | Biological |
| Interventions | interleukin-4 PE38KDEL cytotoxin |
| Start date | Jan 1, 2002 |
| Primary completion | May 1, 2003 |
| Completion | Jul 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: